Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma

• Published in: Oral oncology 2005-03, Vol.41 (3), p.276-282
• Main Authors: Obara, Seiji, Yamamoto, Kazumi, Hosogai, Nao, Yoshimura, Yasuro
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Biomarkers, Tumor - analysis; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - enzymology; Carcinoma, Squamous Cell - therapy; Chemosensitivity; Combined Modality Therapy; Dihydropyrimidine dehydrogenase; Dihydrouracil Dehydrogenase (NADP) - analysis; Female; Humans; Immunohistochemistry; Immunohistochemistry - methods; Male; Medical sciences; Middle Aged; Mouth Neoplasms - drug therapy; Mouth Neoplasms - enzymology; Mouth Neoplasms - therapy; Oral squamous cell carcinoma; Otorhinolaryngology. Stomatology; Quality of Life; Sensitivity and Specificity; Silicates - therapeutic use; Thymidylate synthase; Thymidylate Synthase - analysis; Titanium - therapeutic use; Treatment Outcome; TS-1; Tumors; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology
• ISSN: 1368-8375; 1879-0593
• DOI: 10.1016/j.oraloncology.2004.08.016

Seventeen oral squamous cell carcinoma (SCC) patients underwent chemotherapy with TS-1 (8 males and 9 females, mean age; 75.1 years, range; 47–102 years). TS-1 permitted five cases of oral chemotherapy on an outpatient basis and 8 cases in elder patients over 80-years of age. Excepting five patients who underwent TS-1 therapy as post-operative adjuvant chemotherapy, the therapeutic efficacy of TS-1 in 12 patients with or without irradiation, surgery or chemotherapy resulted in 3 cases of complete response (CR), 6 cases of partial response (PR), 3 cases of stable disease (SD), with no progressive disease (PD) cases (overall response rate; 75%). SCC samples obtained from biopsy were immunohistochemically stained with anti-TS and DPD polyclonal antibody. Although the statistical significance was not clear, the expression of TS and DPD for CR cases was lower than that for SD cases. TS-1 therapy improved quality of life (QOL) especially in elder patients with oral SCC, and our immunohistochemical results suggested the predictive possibilities of TS and DPD expression in response to TS-1.